Fredun Pharmaceuticals expands Furlicks pet brand to 22 SKUs

scanx
Reviewed by
Shriram SScanX News Team
Key Highlights
  • Fredun Pharmaceuticals expands Furlicks from 6 to 22 SKUs
  • Plans to launch 16 new products in 6-9 months
  • New formats include freeze-dried and functional biscuits
  • Brand acquired from USV and Wellbeing Nutrition
powered bylight_fuzz_icon
50395751

*this image is generated using AI for illustrative purposes only.

Fredun Pharmaceuticals is accelerating its entry into the pet wellness market by expanding the Furlicks brand portfolio from 6 to 22 SKUs. The company announced on September 15, 2026, that it plans to introduce 16 new products over the next 6-9 months, moving beyond its initial oral-strip offerings.

Portfolio expansion details

The expansion marks a significant shift from the brand's current six-SKU oral-strip portfolio. Fredun Pharmaceuticals aims to diversify formats to include dissolving strips, cold-extruded, air-dried and freeze-dried products, alongside functional biscuits. This move allows the brand to address a wider range of pet-care occasions while maintaining its focus on convenience and everyday wellness.

The new products will cover existing categories such as skin and coat, gut health, joint care, calming, oral care, and multivitamins, but will now be available in these broader functional nutrition formats. This represents the first phase of a larger product roadmap intended to build Furlicks into a comprehensive, innovation-led platform for the Indian market.

Parameter Details
Brand Furlicks
Current SKU count 6
Target SKU count (Phase 1) 22
New products planned 16
Timeline Next 6-9 months
New formats Dissolving strips, cold-extruded, air-dried, freeze-dried, functional biscuits

Strategic context

Furlicks was acquired by Fredun Pharmaceuticals from USV and Wellbeing Nutrition. Mr. Fredun Medhora, MD & CFO, stated that the acquisition was driven by the potential to build a meaningful business around a differentiated proposition rather than simply adding another brand.

The company intends to leverage its strengths in manufacturing, R&D, and product development to accelerate innovation. While Furlicks is already available online across India, the next phase focuses on deepening the portfolio and strengthening accessibility. The goal is to establish Furlicks as a trusted, accessible, and relevant holistic pet-wellness brand for millions of pet parents in India.

Historical Stock Returns for Fredun Pharmaceuticals

1 Day5 Days1 Month6 Months1 Year5 Years
-3.51%-2.78%-8.22%-8.06%-8.06%-8.06%

How will the increased production complexity of diverse formats like freeze-dried and cold-extruded products impact Fredun's manufacturing costs and gross margins?

What specific distribution channels will Fredun prioritize to move Furlicks beyond its current online-only presence into offline retail in India?

How does Fredun plan to differentiate Furlicks from established international pet wellness brands entering the Indian market with similar functional nutrition offerings?

like20
dislike

Fredun Pharmaceuticals shares permitted to trade on NSE from August 17

scanx
Reviewed by
Ritika DScanX News Team
Key Highlights

Fredun Pharmaceuticals Limited has secured permission from the National Stock Exchange of India Limited to commence trading of its equity shares starting August 17, 2026. The listing expands the company's market presence alongside its existing BSE listing. Shares will trade under the symbol FREDUN with a face value of ₹10.

powered bylight_fuzz_icon
48526508

*this image is generated using AI for illustrative purposes only.

Fredun Pharmaceuticals equity shares have been permitted to trade and admitted to dealings on the National Stock Exchange of India Limited (NSE) with effect from August 17, 2026. The company disclosed the intimation pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The admission follows NSE Circular Ref. No. 1355/2026 dated August 14, 2026, issued under Regulation 3.1.1 of the National Stock Exchange (Capital Market) Trading Regulations, Part A. Fredun Pharmaceuticals is already listed on BSE Limited.

Trading Details

The equity shares will commence trading on the NSE under the following parameters:

Particulars Details
Company Name Fredun Pharmaceuticals Limited
NSE Symbol FREDUN
Date of Commencement August 17, 2026
Face Value ₹10
Nature of Securities Equity

The company’s registered office is located in Mumbai, and its factory is situated in Palghar. Fredun Nariman Medhora, Managing Director, signed the disclosure.

Historical Stock Returns for Fredun Pharmaceuticals

1 Day5 Days1 Month6 Months1 Year5 Years
-3.51%-2.78%-8.22%-8.06%-8.06%-8.06%

How might the dual listing on NSE and BSE impact Fredun Pharmaceuticals' liquidity and market capitalization compared to its previous BSE-only status?

What is the expected initial trading volume and price discovery range for FREDUN on the NSE given its historical performance on the BSE?

Are there any upcoming product launches or regulatory approvals that could drive investor sentiment immediately following the August 17 listing?

like18
dislike

More News on Fredun Pharmaceuticals

1 Year Returns:-8.06%